FDA warns Eatontown, NJ-based Avertix Medical about Quality System, Medical Device Reporting, and Correction and Removal violations in its production of a coronary syndrome event detector.
FDA warns India’s Patcos Cosmetics that it is marketing adulterated over-the-counter drug products that have significant violations of CGMPs.
FDA warns Eatontown, NJ-based Avertix Medical about Quality System, Medical Device Reporting, and Correction and Removal violations in its production of a coronary syndrome event detector.
FDA warns India’s Patcos Cosmetics that it is marketing adulterated over-the-counter drug products that have significant violations of CGMPs.
FDA issues a draft guidance encouraging drug developers to adopt new approach methodologies as part of a broader effort to reduce reliance on animal testing and improve the prediction of human drug safety.
FDA warns Parker, CO-based Oralabs about CGMP violations in its work as a contract drug manufacturer.
